Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

50
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
50
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathy.

Cardiovascular research·2026
Same author

RBM20 variants disrupt Ca<sup>2+</sup> handling and metabolism in dilated and non-compaction cardiomyopathy stem cell models.

Signal transduction and targeted therapy·2026
Same author

Rethinking Myocarditis and Genetic Susceptibility in Severe Paediatric Cardiomyopathy.

European journal of heart failure·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy.

Circulation. Genomic and precision medicine·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Minimally Invasive Transverse Aortic Constriction in Mice
07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

20.8K

Mavacamten en la miocardiopatía hipertrófica no obstructiva sintomática

Milind Y Desai1,2, Anjali T Owens3, Theodore Abraham4

  • 1Hypertrophic Cardiomyopathy Center, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland.

The New England journal of medicine
|September 1, 2025
PubMed
Resumen

Mavacamten no mejoró significativamente la capacidad de ejercicio ni la salud reportada por el paciente en la miocardiopatía hipertrófica no obstructiva (MHC). Se necesita más investigación para comprender su papel en esta población de pacientes.

Más Videos Relacionados

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Minimally Invasive Transverse Aortic Constriction in Mice
07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

20.8K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

Área de la Ciencia:

  • Cardiología
  • Farmacología
  • Ensayos clínicos

Sus antecedentes:

  • Mavacamten está aprobado para el tratamiento de la cardiomiopatía hipertrófica sintomática (HCM).
  • Su eficacia en la CMH no obstructiva no está bien establecida.
  • Este estudio investiga los efectos de mavacamten en pacientes con CMH sintomática no obstructiva.

Objetivo del estudio:

  • Evaluar la eficacia de mavacamten para mejorar la capacidad funcional.
  • Evaluar el impacto de mavacamten en el estado de salud informado por el paciente en HCM no obstructiva.
  • Determinar si mavacamten ofrece beneficios más allá del placebo en este grupo de pacientes.

Principales métodos:

  • Un ensayo internacional de fase 3, doble ciego, controlado con placebo.
  • 289 pacientes recibieron mavacamten y 291 recibieron placebo durante 48 semanas.
  • Efectos primarios: cambio en el pico de absorción de oxígeno y puntuación clínica resumida del Cuestionario de Cardiomiopatía de Kansas City (KCCQ-CSS).

Principales resultados:

  • Mavacamten mostró una tendencia no significativa hacia una mejor absorción máxima de oxígeno (diferencia de 0,47 ml/ kg/ min, P=0,07).
  • Las puntuaciones KCCQ-CSS mejoraron ligeramente con mavacamten (2,7 puntos de diferencia, P=0,06), pero no significativamente.
  • Las reacciones adversas, incluida la reducción de la fracción de eyección, fueron más frecuentes con mavacamten.

Conclusiones:

  • Mavacamten no demostró mejoras estadísticamente significativas en la capacidad funcional o en los síntomas en comparación con el placebo en la CMH no obstructiva.
  • El fármaco no cumplió los objetivos primarios en esta población de estudio.
  • Puede ser necesaria una investigación adicional para aclarar el papel de mavacamten en la CMH no obstructiva.